Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 4286
Gene Symbol: MITF
MITF
0.400 GeneticVariation disease BEFREE Xp11 rearrangement in renal cell carcinoma (RCC) typically involves gene fusion to the gene encoding transcription factor E3 (TFE3), a member of the microphthalmia-associated transcription factor family on chromosome Xp11.2. 30908700 2019
Entrez Id: 596
Gene Symbol: BCL2
BCL2
0.100 Biomarker disease BEFREE XIAP impairs mitochondrial function during apoptosis by regulating the Bcl-2 family in renal cell carcinoma. 29731840 2018
Entrez Id: 7490
Gene Symbol: WT1
WT1
0.040 AlteredExpression disease BEFREE WT1 demonstrated lower RNA expression in ccRCC compared with renal cortical tissue, whereas hTERT was increased, showing a negative correlation between WT1 and hTERT (P=0.005). 20842112 2010
Entrez Id: 29126
Gene Symbol: CD274
CD274
0.100 Biomarker disease BEFREE With an armamentarium encompassing 13 drugs that exploit seven unique therapeutic mechanisms (ie, cytokines, vascular endothelial growth factor receptor, mTORC1, cMET/AXL, fibroblast growth factor receptor, programmed cell death-1 and programmed death-ligand 1, and cytotoxic T-cell lymphocyte associated-4) to treat metastatic renal cell carcinoma, one of the imminent clinical questions concerning care of patients with metastatic ccRCC is how a personalized treatment strategy, through rationally combining and sequencing different therapeutic modalities, can be formulated to offer the best clinical outcome for individual patients. 30372397 2018
Entrez Id: 558
Gene Symbol: AXL
AXL
0.100 Biomarker disease BEFREE With an armamentarium encompassing 13 drugs that exploit seven unique therapeutic mechanisms (ie, cytokines, vascular endothelial growth factor receptor, mTORC1, cMET/AXL, fibroblast growth factor receptor, programmed cell death-1 and programmed death-ligand 1, and cytotoxic T-cell lymphocyte associated-4) to treat metastatic renal cell carcinoma, one of the imminent clinical questions concerning care of patients with metastatic ccRCC is how a personalized treatment strategy, through rationally combining and sequencing different therapeutic modalities, can be formulated to offer the best clinical outcome for individual patients. 30372397 2018
Entrez Id: 4233
Gene Symbol: MET
MET
0.600 GeneticVariation disease BEFREE Wilms' tumour and the WT-1 gene, renal cell carcinoma and the c-met receptor tyrosine kinase gene), some to be caused by mutations in genes expressed during normal development (e.g. renal cell carcinoma and the TSC-2 gene, renal cell carcinoma of the clear cell variety and the VHL gene). 10535327 1999
Entrez Id: 4524
Gene Symbol: MTHFR
MTHFR
0.050 GeneticVariation disease BEFREE While, allele T of MTHFR rs1801133 could decrease the risk of RCC (OR=0.62, 95% CI=0.40-0.97). 26191297 2015
Entrez Id: 2475
Gene Symbol: MTOR
MTOR
0.600 Biomarker disease BEFREE While vascular endothelial growth factor-targeted therapy and mammalian target of rapamycin inhibition are effective strategies in treating clear cell renal cell carcinoma (ccRCC), the most effective therapeutic approach for patients with non-clear cell RCC (non-ccRCC) is unknown. 27939075 2017
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.100 AlteredExpression disease BEFREE While this mechanism has been described as leading to progressive nephron loss, p16(INK4a) upregulation in renal cell carcinoma has been linked to a disease-specific improved patient survival rate. 22521293 2012
Entrez Id: 4495
Gene Symbol: MT1G
MT1G
0.040 AlteredExpression disease BEFREE While alterations in the basal level of expression of MT-1E, MT-1F and MT-1X genes remained unchanged, significant up-regulation of MT-2A and down-regulation of MT-1A and MT-1G transcripts was observed in RCC tissue specimens when compared with controls. 11053642 2000
Entrez Id: 4489
Gene Symbol: MT1A
MT1A
0.010 AlteredExpression disease BEFREE While alterations in the basal level of expression of MT-1E, MT-1F and MT-1X genes remained unchanged, significant up-regulation of MT-2A and down-regulation of MT-1A and MT-1G transcripts was observed in RCC tissue specimens when compared with controls. 11053642 2000
Entrez Id: 4493
Gene Symbol: MT1E
MT1E
0.030 AlteredExpression disease BEFREE While alterations in the basal level of expression of MT-1E, MT-1F and MT-1X genes remained unchanged, significant up-regulation of MT-2A and down-regulation of MT-1A and MT-1G transcripts was observed in RCC tissue specimens when compared with controls. 11053642 2000
Entrez Id: 2538
Gene Symbol: G6PC
G6PC
0.020 GeneticVariation disease BEFREE While a single case of renal cancer has been reported in a GSDI patient, a clear cell renal carcinoma was recently observed in one K.G6pc-/- mouse (out of 36 studied mice) at a later stage of the disease. 29869165 2018
Entrez Id: 3558
Gene Symbol: IL2
IL2
0.100 Biomarker disease BEFREE While IL-2 targets anti-tumor cytotoxic lymphocytes (CTLs) for the treatment of patients with melanoma or renal cell carcinoma, IL-2 directed at regulatory T (Treg) cells could have potential therapeutic value in several immune-related diseases including chronic graft-versus-host disease (cGVHD), type 1 diabetes (T1D) and systemic lupus erythematosus (SLE). 30415086 2019
Entrez Id: 7422
Gene Symbol: VEGFA
VEGFA
0.100 Biomarker disease BEFREE While vascular endothelial growth factor-targeted therapy and mammalian target of rapamycin inhibition are effective strategies in treating clear cell renal cell carcinoma (ccRCC), the most effective therapeutic approach for patients with non-clear cell RCC (non-ccRCC) is unknown. 27939075 2017
Entrez Id: 239
Gene Symbol: ALOX12
ALOX12
0.020 AlteredExpression disease BEFREE While 5- and 12-LOX expression levels were slightly detected in NK tissues, marked expressions of 5- and 12-LOX were detected in RCC tissues. 15944770 2005
Entrez Id: 246
Gene Symbol: ALOX15
ALOX15
0.020 AlteredExpression disease BEFREE While 5- and 12-LOX expression levels were slightly detected in NK tissues, marked expressions of 5- and 12-LOX were detected in RCC tissues. 15944770 2005
Entrez Id: 50947
Gene Symbol: BHD
BHD
0.050 GeneticVariation disease BEFREE Whereas kidney-specific deletion of the Bhd gene in mice is known to result in polycystic kidney disease (PKD) and renal cell carcinoma, the roles of Fnip1 in renal cell development and function are unclear. 29897930 2018
Entrez Id: 55845
Gene Symbol: BRK1
BRK1
0.030 Biomarker disease BEFREE Whereas 9 out of 10 families with ccRCC retained HSPC300 in the germline, loss of the HSPC300 locus was associated with mild clinical presentation of the disease in 6 out of 8 families. 17311301 2007
Entrez Id: 389658
Gene Symbol: ALKAL1
ALKAL1
0.010 PosttranslationalModification disease BEFREE When the DNA methylation status of the FAM150A gene, a marker of the CpG island methylator phenotype specific to clear cell renal cell carcinoma (ccRCC), was examined in 98 patients with ccRCC, bulk specimens of tumorous tissue including cancer cells showing DNA methylation of the FAM150A gene were easily identifiable by simply viewing the differentiated chromatograms, even when the cancer cell content was low. 29520901 2018
Entrez Id: 10228
Gene Symbol: STX6
STX6
0.010 AlteredExpression disease BEFREE When stratifying the data based on histological subtype, the papillary RCC subtype exhibited a significant correlation between syntaxin 6 expression and survival. 30816681 2019
Entrez Id: 768
Gene Symbol: CA9
CA9
0.100 GeneticVariation disease BEFREE When applied to blood samples from three RCC patients treated with intravenous infusions of scFv(G250)(1) T cells, the kinetics of scFv(G250)(1) T cell counts as detected by flow cytometry were similar to those detected by real-time PCR, although PCR allowed detection of transduced T cells over a longer period of time (i.e., for patient 3, 7 versus 32 days, respectively). 16390276 2005
Entrez Id: 407029
Gene Symbol: MIR30A
MIR30A
0.090 Biomarker disease BEFREE Western blotting, immunohistochemistry, luciferase reporter assays, and flow cytometry were employed to investigate the mechanisms of the effect of miR-30a-5p on ccRCC Results: MiR-30a-5p was down-regulated in ccRCC and related to the clinicopathological factors and prognosis of ccRCC. 29073630 2017
Entrez Id: 558
Gene Symbol: AXL
AXL
0.100 AlteredExpression disease BEFREE Western blotting was utilized to determine Axl protein levels in six out of the 20 pairs of the normal/RCC matched pairs. 14565870 2003
Entrez Id: 100505994
Gene Symbol: LUCAT1
LUCAT1
0.030 Biomarker disease BEFREE Western blotting was performed to evaluate the underlying mechanisms of LUCAT1 in ccRCC progression. 30032137 2018